Hyderabad Telangana, India

Rajender Kumar Potlapally

USPTO Granted Patents = 4 

Average Co-Inventor Count = 5.3

ph-index = 1


Company Filing History:


Years Active: 2002-2013

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Rajender Kumar Potlapally: Innovator in Antidiabetic Compounds

Introduction

Rajender Kumar Potlapally is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antidiabetic agents. With a total of 4 patents to his name, Potlapally's work has the potential to impact the treatment of diabetes significantly.

Latest Patents

One of his latest patents is for a novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt. This invention relates to a pharmaceutical composition that includes this novel crystalline form and a pharmaceutically acceptable carrier. The new crystalline form is reported to be more active as an antidiabetic agent compared to previously known compounds. Another significant patent involves an improved process for the preparation of novel antidiabetic compounds, where the compounds have specific structural formulas that enhance their efficacy.

Career Highlights

Potlapally has worked with prominent organizations such as Dr. Reddy's Laboratories and Dr. Reddy's Research Foundation. His experience in these institutions has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Throughout his career, Potlapally has collaborated with notable colleagues, including Ramabhadra Sarma Mamillapalli and Om Reddy Gaddam. These collaborations have fostered an environment of innovation and have led to the development of new therapeutic agents.

Conclusion

Rajender Kumar Potlapally's contributions to the field of antidiabetic compounds highlight his role as an influential inventor. His innovative patents and collaborations reflect his commitment to advancing pharmaceutical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…